Tuesday, September 22, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 15, 2026

Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu

View original at globenewswire.com
Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu MAINZ, Deutschland, 15…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Forward-looking statements in this press release are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

    60% confidence

  • BioNTech is intensifying its focus on its growing late-stage oncology pipeline while continuing early research and development aimed at long-term innovations.

    60% confidence

  • BioNTech aims to sustainably improve treatment options for people with cancer and develop innovative drugs with tumor-cross-cutting or synergistic potential to address cancer across all stages of the disease.

    60% confidence

  • Readers are advised to review Risk Factors in BioNTech's Form 6-K report for the period ending March 31, 2026, and subsequent SEC filings.

    60% confidence

Data points we hold from this source

BioNTech SE · supervisory board size8 members
BioNTech SE · shareholder attendance92 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com
Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu — Source | Via News | Via News